previous arrow
next arrow
Slider

Please find below the latest news from Yourgene Health, formerly Premaitha Health. We also share this news across social media networks.

  • 15 October 2019 - American Society of Human Genetics Annual Meeting attendance +

    Yourgene Health plc

    (“Yourgene” or the “Group”)

    American Society of Human Genetics Annual Meeting attendance

    Manchester, UK – 15 October 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it will be exhibiting at the American Society of Human Genetics (“ASHG”) Annual Meeting in Houston, Texas which runs from Tuesday 15 October to Saturday 19 October 2019 (Booth no. 101).

    The ASHG Annual Meeting is the first time the Company has taken an

    Read More
  • 14 October 2019 - Half year trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group”)

    Half year trading update

    Manchester, UK – 14 October 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides a positive trading update for the six months to 30 September 2019.

    Revenues for the six months to 30 September 2019 were £7.8m, up 98% on the equivalent prior year period (six months to 30 September 2018: £3.9m), and in line with management expectations. International revenues continue to show

    Read More
  • 26 September 2019 - CE-IVD Certification renewal +

    CE-IVD Certification renewal

    Manchester, UK – 26 September 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that in preparation for a 2020 product launch and as a contingency for BREXIT, the Company has successfully transferred its quality accreditation process to a new Notified Body, BSI NL (Netherlands), allowing the Company to continue to sell its systems in the European Economic Area (EEA).

    As part of this transfer, Yourgene has been issued with a

    Read More
  • 18 September 2019 - Launch of DPYD chemotoxicity diagnostic assay +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Launch of DPYD chemotoxicity diagnostic assay

    Test to identify cancer patients at risk of lethal side effects from chemotherapy

    Manchester, UK – 18 September 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the launch of the Company’s first oncology product, the Elucigene DPYD assay (“Elucigene DPYD”), a new chemotoxicity diagnostic assay.

    Elucigene DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase

    Read More
  • 20 August 2019 - Notice of AGM  +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Notice of AGM

    Manchester, UK – 20 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Annual General Meeting (AGM) will be held at 4:00pm on 17 September 2019 at Citylabs 1.0, Nelson Street, Manchester M13 9NQ.

    Ahead of the meeting, the Chair will introduce shareholders to newly appointed Non-executive Directors, Dr John Brown CBE and Jonathan Seaton. In addition, the Company’s CEO, Lyn

    Read More
  • 16 August 2019 - Directorate Change Appointment of business development sector specialist as Non-executive Director +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Directorate Change

    Appointment of business development sector specialist as Non-executive Director 

    Manchester, UK – 16 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Jonathan Seaton to the Board of Directors as a Non-executive Director, with immediate effect .

    Jonathan has extensive experience working for leading global life sciences and diagnostic companies having worked on more than 40 M&A transactions as well as strategic

    Read More
  • 29 July 2019 - Appointment of Director +

    Yourgene Health plc

    (“ Yourgene ”, the “ Company ” or the “ Group ”)

    Appointment of Director

    Manchester, UK – 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the appointment of Dr John Brown CBE to the Board of Directors as a Non-executive Director with immediate effect.   Dr Brown will act as the Senior Independent Director on the Board.

    Dr Brown

    Read More
  • 10 July 2019 - Results for the Year Ended 31 March 2019, 
Business Update and Director Change +

    Yourgene Health plc

    (“ Yourgene ” or the “ Company ” or the “ Group ”)

    Results for the Year Ended 31 March 2019,
    Business Update and Director Change

      Manchester, UK – 10 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its results for the year ended 31 March 2019, and provides a business update.

    Full year results summary :

    • Comprehensive profit of

    Read More
  • 24 June 2019 - Yourgene participates in key global conferences +

    Yourgene Health plc
    (“Yourgene Health” or the "Company")

    Yourgene participates in key global conferences

    Manchester, UK - 24 June 2019: Yourgene Health (AIM : YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its participation at key conferences to raise the profile of its reproductive health products and services.

    European Society Human Genetics

    Yourgene recently attended the European Human Genetics Conference, organised by the European Society of Human Genetics. The event – held

    Read More
  • 25 April 2019 - Completion of Acquisition +

    THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS DOCUMENT.

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Read More
  • 17 April 2019 - Proposed acquisition of Delta Diagnostics (UK) Limited +

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Proposed acquisition of Delta Diagnostics (UK) Limited ("Elucigene")
    and
    Proposed placing of a minimum of 92,682,928new Ordinary Shares
    and
    Proposed subscription for 4,878,048new Ordinary Shares

    Highlights

    ● Proposed acquisition of Elucigene, a leading molecular diagnostics manufacturer and developer, complementary to Yourgene’s current and planned product offering

    ●  Acquisition consideration of £9.2 million (comprising £6.3 million cash and £2.9 million equity), includes £0.4 million of net cash, representing an enterprise

    Read More
  • 8 April 2019 - Full-year Trading Update +

    Yourgene Health plc

    (“Yourgene”, the “Company” or the “Group”)

    Full-year Trading Update

    Manchester, UK 8 April 2019 : Yourgene Health (AIM : YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading update for the year ended 31 March 2019.

    Trading Highlights

    ●  Unaudited revenues were ahead of market expectations, increasing by 45% to over £8.9m (2018: £6.1m), with growth in all active regions
    ●  Test volumes increased by 67% to

    Read More
  • 25 March 2019 - Yourgene raises IONA® test awareness in Egypt with British Ambassador (2) +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene raises IONA® test awareness in Egypt with British Ambassador

    Manchester, UK 25 March 2019 : Yourgene Health ( AIM : YGEN ) , the international molecular diagnostics group which commercialises genetic products and services, has held an event in Egypt to raise awareness of the IONA® test, a non-invasive prenatal DNA test for Down’s syndrome, amongst the clinical community.

    The event was attended by His Excellency Sir Geoffrey Adams, the British

    Read More
  • 18 February 2019 - Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene Health Announces Capital and Commercial Restructuring

    with Major Shareholder

    Manchester, UK – 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a restructuring of its financial and commercial relationship with Life Technologies Limited (“Life Technologies”).

    Lyn Rees, CEO of Yourgene Health, commented:

    “I am delighted with the restructuring of our relationship with Life Technologies, which places Yourgene

    Read More
  • 8 January 2019 - High throughput NIPT solution for clinical laboratories +

    Yourgene Health plc
    (“Yourgene”, the “Company”)
     
    Yourgene launches Sage™ 32 plex
     
    High throughput NIPT solution for clinical laboratories
     
    Manchester, UK – 8 January 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, is pleased to announce the launch of the Sage™ 32 plex test, a new high throughput non-invasive prenatal testing (“NIPT”) and analysis solution for clinical laboratories. 
     
    Sage™ 32 plex uses the latest
    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen